Special Issue "Recent Advances in Drug Therapy for Glioblastoma"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 30 April 2022.

Special Issue Editor

Dr. Juan Manuel Sepúlveda-Sánchez
E-Mail Website
Guest Editor
Instituto de investigación I+12, Hospital 12 de Octubre, 28041 Madrid, Spain
Interests: glioblastoma; glioma; immunotherapy; targeted therapies; tumor microenvironment; epigenetics; brain tumors; neuro-oncology

Special Issue Information

Dear Colleagues,

Glioblastomas are highly aggressive tumors of the brain that are resistant to radiotherapy and temozolomide, the only treatments currently available. Therefore, effort is necessary to find novel therapeutic approaches and alternative targets in order to enhance the survival of these patients. In fact, the median overall survival after surgery and the standard treatment with radiotherapy and temozolomide is 14–16 months, and there is no standard second line treatment since lomustine and bevacizumab have modest efficacy.

Despite the lack of clear advances in the treatment of glioblastoma, molecular and cellular studies have significantly improved the knowledge of glioma biology, particularly in the fields of microenvironment regulation, tumor immunology, and in oncogenic signaling pathways control.

Clinical and translational researchers are getting the most out of these new findings in order to develop new drugs targeting not only tumor growth pathways but also the glioma microenvironment. In this respect, this Special Issue will focus on new therapeutic approaches that try to overcome previous failures in glioblastoma management. We welcome preclinical and clinical studies evaluating new targets in glioblastoma and also new drugs with a classic mechanism of action that could improve the survival rate of temozolomide and lomustine.

Dr. Juan Manuel Sepúlveda-Sánchez
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • glioblastomas
  • novel therapeutics
  • new drugs

Published Papers

This special issue is now open for submission.
Back to TopTop